676254-75-4

Upstream product

• 104701-87-3 (2S)-3-(tert-butyl-dimethyl-silyloxy)-2-methyl-propanal 
• 676254-73-2 (2S,3R,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-non-4-yn-3-ol 
• 676254-72-1 (2S,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-non-4-yn-3-one 
• 676254-71-0 tert-Butyl-((2S,3S,4S)-3-methoxymethoxy-2,4-dimethyl-hex-5-ynyloxy)-dimethyl-silane 
• 202119-27-5 (2S,3S,4S)-1-((tert-butyldimethylsilyl)oxy)-2,4-dimethylhex-5-yn-3-ol 
• 107-30-2 chloromethyl methyl ether 
• 676254-74-3 (2S,3S,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-nonan-3-ol 

Downstream Products

• 676254-80-1 C₄₃H₇₄O₆Si₃ 
• 676254-81-2 (3R,4R,5S,8S,9S,10S)-11-(tert-butyldimethylsilyloxy)-3-(tert-butyldiphenylsilyloxy)-5,9-bis(methoxymethoxy)-4,8,10-trimethyl-undec-1-yne 

Relevant academic research and scientific papers

Applications of chiral allenylzinc additions and Noyori asymmetric reductions to an enantioselective synthesis of a C3-C13 precursor of the polyketide phosphatase inhibitor cytostatin

A 12-step synthesis of a C3-C13 precursor of the protein phosphatase inhibitor cytostatin is described. Key stereocenters were introduced by a chiral allenylzinc addition and Noyori asymmetric-transfer hydrogenation.